Omvoh

News

UEGW delegates hear of strides forward in IBD treatment

Trials of Lilly's Omvoh, Gilead's emvistegrast, Takeda's Entyvio, AbbVie's ABBV-466, and Sanofi/Teva's duvakitug are highlights of UEGW.

News

NICE backs new drugs for Crohn's disease, lymphoma

Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.

News

Lilly nets a second FDA okay for Omvoh, in Crohn's disease

Eli Lilly picks up a second FDA approval for IL-23 inhibitor Omvoh in Crohn's disease, but will it kickstart sales growth?

News

Lilly finally gets FDA OK for ulcerative colitis drug Omvoh

After an earlier rejection, the FDA has approved Eli Lilly’s first-in-class IL-23p19 inhibitor mirikizumab as a treatment for adults with moderately to severely active ulc

UEGW delegates hear of strides forward in IBD treatment

NICE backs new drugs for Crohn's disease, lymphoma

Lilly nets a second FDA okay for Omvoh, in Crohn's disease

Lilly finally gets FDA OK for ulcerative colitis drug Omvoh

HHS doubles down on controversial peptides plan

Discover a new era of healthcare panel engagement: Grounded ...

Omvoh

Editor's Picks